G

GSK

Develops medicines, vaccines, and consumer health

NPI Portfolio and Transformation Lead

Full-Time
No salary listed
Senior
Zebulon, NC, USA
Hybrid
Project & Program ManagementProgram Management

About the job

Requirements
  • At least 7 years of experience leading complex pharmaceutical transformation or strategic programs in a regulated manufacturing environment, with a strong understanding of safety, quality, compliance and operational standards.
  • Ability to translate strategic priorities into executable roadmaps and deliver cross-functional programs through governance, integrated planning, resource alignment, risk management, decision-making and senior stakeholder engagement.
  • Experience leading permanent teams and matrixed cross-functional resources across site-based and central functions, with clear accountability for outcomes and timely escalation.
  • Experience with portfolio governance for strategic initiatives, including prioritization, stage gates, milestone and benefits tracking, performance reporting, and transition to accountable business owners.
  • Experience coordinating operational readiness across people, process, plant, materials and systems.
  • Analytical and communication capability, including the ability to interpret data, assess complex and interdependent scenarios, present options and recommendations, and report performance to senior leadership.
Responsibilities
  • Translate the site transformation strategy and Site Leadership Team-approved priorities into an integrated portfolio roadmap, providing data, options, feasibility assessments, sequencing recommendations, resource requirements and delivery risks to support Site Leadership Team decision-making.
  • Lead end-to-end delivery of the site transformation portfolio, New Product Introduction portfolio, technical transfers and key strategic initiatives designated by the Site Leadership Team, ensuring alignment to approved scope, milestones, business objectives and measurable benefits.
  • Establish and lead fit-for-purpose governance for portfolio projects and designated strategic initiatives, including prioritization, stage gates, integrated plans, performance reporting, risk and issue management, decision tracking and timely escalation. This remit does not extend to routine functional projects or constitute ownership of a general site Project Management Office; functional leaders remain accountable for projects within their normal operational remit.
  • Provide direct leadership to the permanent New Product Introduction team and delivery leadership to cross-functional resources assigned to transformation initiatives. Ensure the organization is appropriately structured, resourced and developed, while assigned resources retain their normal functional reporting lines and accountabilities.
  • Lead integrated delivery planning for regulatory submissions, process validation, technology transfer, operational readiness and inspection readiness. Ensure Quality, Regulatory, Manufacturing Science and Technology, Engineering, Manufacturing and Supply Chain owners have aligned plans, dependencies, milestones and risk mitigations, while functional experts retain technical approval and compliance accountability.
  • Ensure capital projects supporting New Product Introduction, transformation and operational readiness are integrated into the overall portfolio plan, with aligned scope, milestones, dependencies, qualification requirements and risk mitigations. Engineering retains accountability for capital-project execution, technical decisions and applicable engineering standards.
  • Ensure operational readiness across people, process, plant, materials, systems and ways of working, including training, procedures, supply continuity, equipment and facility readiness, and effective transition into routine operations.
  • Drive continuous improvement and sustainable change across the approved portfolio, establishing balanced success measures including on-time delivery, milestone performance, benefits realization, operational readiness, quality and Right First Time, cost performance and risk reduction.
  • Ensure portfolio projects and strategic initiatives deliver approved objectives and measurable benefits through implementation and stabilization; confirm required controls and capabilities are embedded and complete formal handover to the accountable functional owner for sustained performance.
  • Foster a high-performance culture grounded in safety, quality, integrity, inclusion, collaboration and accountability, enabling open escalation, sound decision-making, coaching, development and recognition across the permanent and matrix teams.
Desired Qualifications
  • New Product Introduction, technology transfer, regulatory readiness, validation or inspection-readiness experience.
  • Strategic program and portfolio delivery, including prioritization, integrated planning, governance, dependency management, risk and issue management, decision tracking, benefits realization and formal handover.
  • Strong working knowledge of pharmaceutical manufacturing, current Good Manufacturing Practice expectations, quality systems, operational readiness and regulated change.
  • New Product Introduction and technology-transfer knowledge.
  • Ability to lead through influence across Manufacturing, Quality, Manufacturing Science and Technology, Engineering, Supply Chain, Regulatory, Chemistry, Manufacturing and Controls, and other functions, while maintaining clear accountability boundaries.
  • Stakeholder management, consultation, listening, communication, negotiation and conflict resolution skills, with the ability to engage effectively from shop floor to senior leadership.
  • Strong analytical capability and disciplined use of balanced performance measures covering delivery, readiness, quality, cost, risk reduction and benefits realization.
  • Ability to build and develop high-performing teams through coaching, feedback, recognition, inclusion and clear accountability.
  • Flexibility, adaptability and resilience to work effectively under pressure, manage competing priorities and drive sustainable change.
  • Professional project or program management certification.
  • Lean Six Sigma Green Belt or Black Belt certification.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Associated Press
Oct 19th, 2026
FDA approves Jemperli as first immunotherapy for MSI-H/dMMR rectal cancer, with 68% response

The US Food and Drug Administration (FDA) has approved GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). AnaptysBio, which manages the financial collaboration for the drug, announced the approval on October 19, 2026. The decision rests on the AZUR-1 trial. Among evaluable patients, 68% (98 of 144) had a sustained clinical complete response at 12 months, according to investigator assessment. No recurrences have been reported among responders after a median follow-up of more than two years. Jemperli alone could help eligible patients avoid chemotherapy, radiation, and surgery. Serious adverse reactions occurred in 20% of patients. GSK will present full interim data at the ESMO Congress in Madrid on October 25, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

The Reporter
Oct 15th, 2026
Officials announce $2.9 billion from Merck to expand vaccine and medicine manufacturing in Montco.

Officials announce $2.9 billion from Merck to expand vaccine and medicine manufacturing in Montco. Company is currently in tax dispute with local district, township. PUBLISHED: October 15, 2026 at 1:32 PM EDT UPDATED: October 15, 2026 at 1:38 PM EDT UPPER GWYNEDD - Governor Josh Shapiro and Pennsylvania Department of Community and Economic Development Secretary Rick Siger announced on Wednesday that the state has secured a $2.9 billion investment from Merck global biopharmaceutical company to expand its operations in Montgomery County by the end of 2030. Pennsylvania is investing $5 million in the company's expansion, which will support the manufacturing of lifesaving products and medicine discovery, according to a statement from Shapiro and Siger. As part of the $2.9 billion commitment, Merck is investing $550 million in ADVANCE, a state-of-the-art robotics and AI-enabled drug research and development facility at its West Point Campus, and the nearby Springhouse Innovation Park R&D facility, which will help the company produce life-saving medicines. "My administration has made life sciences a key part of our economic development strategy here in Pennsylvania, and Merck's major investment in Montgomery County is another major win for the commonwealth," said Shapiro in a statement from his office. "We are proud to partner with Merck as they expand their operations in Montgomery County, advance cutting-edge research and manufacturing, and create new opportunities for thousands of Pennsylvanians. The life sciences industry is booming in Pennsylvania and I am committed to winning more investments like this and making sure our commonwealth remains a national leader in innovation, medicine, and manufacturing." A week earlier, also in Montgomery County, Shapiro and Siger announced that pharma giant GSK will invest more than $800 million to expand its facilities in King of Prussia, establishing a biopharmaceutical innovation and manufacturing hub, integrating commercial production, research and development and advanced digital capabilities in a single site. Funding from RCAP. Merck received a funding proposal from DCED for a $5 million Redevelopment Assistance Capital Program grant for the first West Point projects. Shapiro and Siger were at Merck's West Point campus Wednesday to help cut the ribbon on the ADVANCE facility. West Point plays a critical role in global public health, manufacturing over 200 million doses of vaccines a year. "Merck's continued investment in Montgomery County is a testament to Pennsylvania's strength as a global hub for life sciences, innovation, and advanced manufacturing," said Siger. "The commonwealth's $5 million RACP investment is helping support projects that will strengthen Merck's operations, advance the development and manufacturing of critical medicines and vaccines, and reinforce our competitive edge in an industry that is extremely important in Pennsylvania." In July, Upper Gwynedd Township officials announced that Merck was developing plans for a new manufacturing facility on their West Point campus, the most recent of several approved and built since the start of the 2020s, including expanding the existing "Building 45" for labs and office space in October 2020, a new "Building 50" of roughly 101,000 square feet of manufacturing space in February 2021, a new "Building 32" for freezer space approved in May 2021, expansion of the proposed "Building 50" in August 2021, and a new "Building 63A" production facility approved in November 2021. Merck also secured approvals in 2024 for a new "Building 41" toward the center of the company's 320-acre complex and in 2025 secured approvals from the township to swap preservation of wetlands on the site for another parcel elsewhere in the region. In September township officials approved the latest plans, for a vaccine manufacturing facility of roughly 75,000 square feet. The company, township, and North Penn School District have also been in a dispute over the firm's tax bill since early May, when Upper Gwynedd's staff asked that township's commissioners to approve a contract for new assessments of two properties township's comprising the West Point campus. In June the district hired a special counsel to handle the matter, and in September the school board created a new fund to keep Merck tax payments separate, saying the company was 'paying in protest' during the dispute. Joining Shapiro and Riger on Wedneday, Rob Davis, chairman and CEO of Merck, said, "The ADVANCE facility represents the future of clinical development at Merck and underscores our continued commitment to addressing the needs of the patients we serve." "This builds on our longstanding presence in Pennsylvania where we're proud to invest in the people, communities and scientific capabilities that will help drive the next generation of medicines," he said.

Seeking Alpha
Oct 14th, 2026
GSK plans more than 1,200 job cuts in Belgium.

GSK plans more than 1,200 job cuts in Belgium. GSK (GSK) plans to cut up to 1,217 jobs in Belgium as part of a proposed restructuring affecting research and development, production, and international support services, according to multiple Belgian media reports. The plan covers 482 white-collar employees and 735 management positions, according to union ABVV Chemie. Production-floor worker positions are reportedly excluded from the proposed reorganization. GSK (GSK) outlined the restructuring at a special works council meeting on Wednesday, October 14. The proposed changes affect GSK Biologicals, the group's vaccine business, according to a local report. GSK (GSK) employs about 8,500 people across its Belgian sites in Wavre, Rixensart and Gembloux. The proposed cuts follow a reduction of more than 400 jobs in Belgium during 2025, mainly through temporary-contract non-renewals and voluntary departure. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market.

WZUU
Oct 14th, 2026
GSK to cut up to 1,217 jobs in Belgium, L'Echo says.

GSK to cut up to 1,217 jobs in Belgium, L'Echo says. BRUSSELS, Oct 14 (Reuters) - British biopharmaceutical company GSK is planning to cut up to 1,217 jobs from its Belgium locations, Belgian newspaper L'Echo reported on Wednesday. - The company announced the plan to unions earlier on Wednesday - The company and unions did not immediately respond to requests for comment (Reporting by Makini Brice;Editing by Elaine Hardcastle) Now Playing Too Late For Love DEF LEPPARD